文献速递药物相互作用治疗药物监测与药物基因组学

Ningetinib与吉非替尼在NSCLC患者中的药物相互作用及CYP1A1和外排转运体机制

Drug interaction of ningetinib and gefitinib involving CYP1A1 and efflux transporters in non-small cell lung cancer patients.
PubMed 文献 · Br J Clin Pharmacol · 2020-11-15

本研究在NSCLC患者中探究Ningetinib与吉非替尼联用的药物相互作用及M1高暴露机制。结果显示联用后M1血浆暴露降低80%而Ningetinib不受影响,CYP1A1介导M1生成且吉非替尼为其强抑制剂(Ki=0.095 μM),M1为P-gp和BCRP底物,Ningetinib和吉非替尼均为其抑制剂。结论认为M1高暴露源于Ningetinib抑制外排及低组织亲和力,吉非替尼抑制M1生成但未影响Ningetinib药动学。

要点

  • 联用吉非替尼使M1血浆暴露降低80%,Ningetinib暴露不受影响。
  • 吉非替尼为CYP1A1强抑制剂,Ki值为0.095 μM。
  • M1为P-gp和BCRP底物,Ningetinib和吉非替尼均为其抑制剂。

核心结论

  • NSCLC患者中M1高血浆暴露归因于Ningetinib抑制M1外排及其低组织亲和力。
  • 联用时吉非替尼抑制M1生成,但因M1体内代谢产率低,Ningetinib药动学未受影响。
  • 抑制CYP1A1可能增加Ningetinib在靶组织中的浓度,联合用药的长期安全性和有效性需评估。

研究设计与样本

  • 研究纳入NSCLC患者,并进行体外代谢与转运实验。
  • 采用氘代M1在ICR小鼠中研究Ningetinib和吉非替尼对M1外排的影响。

主要发现

  • 联用Ningetinib与吉非替尼后,M1血浆暴露降低80%,而Ningetinib暴露未受影响。
  • 体外实验表明CYP1A1主要负责M1形成,吉非替尼为其强抑制剂,Ki值为0.095 μM。
  • M1被鉴定为外排转运体P-gp和BCRP的底物,Ningetinib和吉非替尼均为其抑制剂,与小鼠结果一致。
  • 然而在Ningetinib存在时,吉非替尼对体内外排的抑制作用可忽略不计。

临床怎么用

  • 临床联用Ningetinib与吉非替尼时需关注CYP1A1介导的相互作用对靶组织浓度的潜在影响。
  • 联合用药的长期安全性和有效性应进行临床评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Ningetinib is a tyrosine kinase inhibitor for the treatment of non-small cell lung cancer (NSCLC). The present study aims to investigate the drug interaction of ningetinib and gefitinib and the mechanism of high plasma exposure of N-demethylated ningetinib (M1) in NSCLC patients. METHODS: Patients with NSCLC were recruited. Metabolism and transport assays were performed using in vitro models. Deuterated M1 was used to study the effects of ningetinib and gefitinib on M1 efflux in Institute of Cancer Research (ICR) mice. RESULTS: Upon co-administration of ningetinib with gefitinib, the plasma exposure of M1 was reduced by 80%, whereas that of ningetinib was not affected. In vitro experiments indicated that CYP1A1 was primarily responsible for M1 formation. Gefitinib was demonstrated to be a strong inhibitor of CYP1A1 with Ki value of 0.095 μM. M1 was identified as a substrate of efflux transporters P-gp and BCRP, while ningetinib and gefitinib were demonstrated to be their inhibitors, which was consistent with the results in mice. However, the inhibitory effect of gefitinib on efflux in vivo was negligible in the presence of ningetinib. CONCLUSION: The high plasma exposure of M1 in patients was attributed to the inhibition of M1 efflux by ningetinib and its low tissue affinity. When co-administered, gefitinib inhibited the formation of M1, but due to the low metabolic yield of M1 in vivo, the pharmacokinetics of ningetinib was not influenced. Inhibition of CYP1A1 may increase the concentration of ningetinib in target tissues, and the long-term safety and efficacy of ningetinib combined with gefitinib should be evaluated.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Liu L, Wang Q, Xie C, et al. Drug interaction of ningetinib and gefitinib involving CYP1A1 and efflux transporters in non-small cell lung cancer patients. Br J Clin Pharmacol. 2020. PMID: 33098714. doi:10.1111/bcp.14621

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。